Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$324.55B | 22x | 1.45 | HK$106 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.9% Upside | Upgrade to Pro+ | |
BeOne Medicines HK | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$270.49B | -199.9x | -2.97 | HK$190 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.6% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$148.98B | 37.9x | 0.52 | HK$36.66 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.5% Downside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$117.72B | -133.7x | 12.06 | HK$127.80 | 4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.3% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$110.39B | -150.3x | 0.53 | HK$473.40 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
TransThera Sciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$65.92B | -236x | -10 | HK$166.10 | 46.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$57.61B | -45.2x | -1.54 | HK$95.60 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -23.2% Downside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$57.28B | 39.8x | -1.45 | HK$24.52 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.3% Upside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$48.86B | 157.8x | -2.1 | HK$43.46 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.6% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$35.55B | -276.3x | 0.58 | HK$16.27 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41% Upside | Upgrade to Pro+ | |
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$29.06B | -117.2x | -2.35 | HK$14.62 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.8% Upside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$26.64B | -18.8x | 0.11 | HK$72.50 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.4% Upside | Upgrade to Pro+ | |
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$24.76B | 81.8x | 0.63 | HK$19.94 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.4% Upside | Upgrade to Pro+ | |
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$19.52B | -66x | -1.13 | HK$66.25 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.5% Upside | Upgrade to Pro+ | |
MiRXES Holding | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$19.29B | -16.5x | HK$70.60 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.6% Upside | Upgrade to Pro+ | ||
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$13.31B | 53x | 0.25 | HK$13.70 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -47.8% Downside | Upgrade to Pro+ | |
Nanjing Leads Biolabs | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$13.18B | -33.4x | HK$66.25 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21% Upside | Upgrade to Pro+ | ||
CF PharmTech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$11.71B | 378.5x | HK$28.42 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
GenFleet Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$10.77B | -1x | HK$31.20 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$10.70B | 72.1x | 0.08 | HK$15.91 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.4% Upside | Upgrade to Pro+ | |
CARsgen Therapeutics Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$9.54B | -18x | -0.73 | HK$17.22 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.6% Upside | Upgrade to Pro+ | |
Biocytogen Pharmaceuticals Beijing | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$9.31B | 75.6x | 0.45 | HK$23.32 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -48.4% Downside | Upgrade to Pro+ | |
Qyuns Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6.47B | -37x | -0.57 | HK$27.28 | 4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.5% Upside | Upgrade to Pro+ | |
TYK Medicines | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6.12B | -21.5x | -0.44 | HK$16.11 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.8% Upside | Upgrade to Pro+ | |
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6.09B | -149.4x | -1.47 | HK$7.73 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -35.2% Downside | Upgrade to Pro+ | |
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.68B | -13.5x | -0.65 | HK$11.48 | 5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medtide | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.34B | 32.3x | 0.48 | HK$30.64 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.8% Upside | Upgrade to Pro+ | |
Visen Pharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.24B | -18.3x | HK$40.40 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Cloudbreak Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.07B | -3.5x | HK$4.85 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Hua Medicine | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.70B | 3.2x | 0.01 | HK$3.79 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Antengene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.67B | -16.5x | -0.27 | HK$5.40 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -46.7% Downside | Upgrade to Pro+ | |
Jiangsu Recbio Technology | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.17B | -5.1x | 0.25 | HK$6.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Clover Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.66B | -3.8x | 1.65 | HK$2.05 | -11.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.52B | -62x | -1.15 | HK$0.61 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Frontage Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.33B | 84.2x | -2.38 | HK$1.15 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.6% Upside | Upgrade to Pro+ | |
Immunotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.29B | -11.1x | -0.36 | HK$3.71 | -12.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HighTide Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.89B | -5.6x | -0.1 | HK$3.30 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genor Biopharma Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.88B | 63.4x | 0.62 | HK$3.59 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioDlink International | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.66B | 201.9x | -11.03 | HK$2.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.6% Upside | Upgrade to Pro+ | |
Jw Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.58B | -2.9x | -1.18 | HK$3.90 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.2% Upside | Upgrade to Pro+ | |
Brii Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.40B | -3.8x | 0.08 | HK$1.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.9% Upside | Upgrade to Pro+ | |
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.39B | -8.1x | -0.15 | HK$13.31 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wuhan YZY Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.32B | -15.5x | -0.27 | HK$6.79 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sunho Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.15B | -12.9x | -0.26 | HK$7.55 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kintor Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$995.53M | -5.8x | -0.07 | HK$2.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Health Inc | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$175.18M | -12.1x | -0.15 | HK$0.18 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laekna | Hong Kong | Healthcare | Biotechnology & Medical Research | -1.14 | HK$14.02 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |